A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
Incyte Corporation
Incyte Corporation
M.D. Anderson Cancer Center
Takeda
Loyola University
Masonic Cancer Center, University of Minnesota
Children's Oncology Group
Dana-Farber Cancer Institute
Hospital Israelita Albert Einstein
St. Jude Children's Research Hospital
Fred Hutchinson Cancer Center